Advertisement
Advertisement
U.S. markets close in 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Pharming Group N.V. (PHAR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
10.74+0.36 (+3.47%)
As of 10:57AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Performance Outlook
Previous Close10.38
Open10.60
Bid10.71 x 800
Ask10.90 x 1200
Day's Range10.60 - 10.74
52 Week Range6.10 - 11.05
Volume1,924
Avg. Volume2,729
Market Cap696.756M
Beta (5Y Monthly)1.39
PE Ratio (TTM)67.12
EPS (TTM)0.16
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
42% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PHAR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pharming Group N.V.
    Daily – Vickers Top Buyers & Sellers for 07/01/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • PR Newswire

    Pharming Group reports financial results for the first half of 2022

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022.

  • PR Newswire

    Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

    Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that a new diagnosis code for reporting cases of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be added to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) by the US Centers for Disease Control and Prevention (CDC). The diagnosis code, D81.82 ‒ Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)

  • CNW Group

    Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

    Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib. Leniolisib has been studied for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents age 12 or older in the European Economic Area (EEA

Advertisement
Advertisement